There are no studies on risk of HRT after RRSO on breast cancer recurrence in premenopausal BRCA1/2-pV carriers or of carriers of pV in other breast and/or ovarian cancer genes or genes of the Lynch-syndrome. This evidence concerns the gene BRCA1 and ovarian cancer.